Boston Scientific (NYSE:BSX) Price Target Raised to $129.00 at Truist Financial

Boston Scientific (NYSE:BSX) had its price target upped by Truist Financial from $125.00 to $129.00 in a report issued on Wednesday, MarketBeat reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

Several other equities research analysts also recently commented on BSX. Leerink Partners lifted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Finally, BTIG Research boosted their price target on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $120.67.

Boston Scientific Stock Down 1.9%

NYSE:BSX opened at $95.78 on Wednesday. The firm’s 50 day simple moving average is $103.30 and its 200 day simple moving average is $102.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The company has a market cap of $141.91 billion, a PE ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $0.62 EPS. The firm’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 over the last quarter. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HM Payson & Co. increased its stake in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. Riverwater Partners LLC increased its stake in Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management increased its stake in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 99 shares in the last quarter. IVC Wealth Advisors LLC increased its stake in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares in the last quarter. Finally, Park Square Financial Group LLC increased its stake in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after purchasing an additional 103 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.